- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
More Than Half of Younger Cancer Patients Have Tried Alternative Therapies
Cancer patients under the age of 65 are much more likely to try alternative and complimentary medicine to ease their symptoms and the side effects of their cancer treatments.
Baby boomers and younger cancer patients are much more open to alternative and complementary medicine compared with older generations, according to a new study.
Jun Mao, MD, director of integrated oncology at the Abramson Cancer Center at the University of Pennsylvania, and colleagues found that patients under the age of 65 were more likely to explore alternative therapies to ease their symptoms and the side effects of their cancer treatments. The researchers attributed this large gap between generations to the social change that took part in the US in the 1960s and 1970s.
The researchers surveyed adults with breast, lung, and gastrointestinal tumors and found that about 59% had tried at least one form of complimentary or alternative therapy such as acupuncture, chiropractic care, art therapy, massage, yoga, tai chi, special diets, or herbal supplements, since their diagnosis. The average age of participants was 59 years with 63% women and most were white and college educated.
Read more at Reuters: http://reut.rs/1JXlhBS
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
